CVA
MCID: CRB039
MIFTS: 67

Cerebrovascular Disease (CVA)

Categories: Blood diseases, Cardiovascular diseases, Neuronal diseases

Aliases & Classifications for Cerebrovascular Disease

MalaCards integrated aliases for Cerebrovascular Disease:

Name: Cerebrovascular Disease 12 54 15
Cerebrovascular Disorders 43 71
Cerebrovascular Accident 12 71
Cerebrovascular Disorder 12 17
Stroke 12
Cva 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6713
ICD9CM 34 437.9
MeSH 43 D002561
NCIt 49 C2938
SNOMED-CT 67 62914000
UMLS 71 C0007820 C0038454

Summaries for Cerebrovascular Disease

Disease Ontology : 12 An vascular disease that is characterized by dysfunction of the blood vessels supplying the brain.

MalaCards based summary : Cerebrovascular Disease, also known as cerebrovascular disorders, is related to basal ganglia cerebrovascular disease and cerebral amyloid angiopathy, app-related, and has symptoms including seizures, edema and tremor. An important gene associated with Cerebrovascular Disease is HOTAIR (HOX Transcript Antisense RNA), and among its related pathways/superpathways are Metabolism of water-soluble vitamins and cofactors and Binding and Uptake of Ligands by Scavenger Receptors. The drugs Glyburide and Nicotinamide have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and testes, and related phenotypes are homeostasis/metabolism and cardiovascular system

Wikipedia : 74 Cerebrovascular disease includes a variety of medical conditions that affect the blood vessels of the... more...

Related Diseases for Cerebrovascular Disease

Diseases related to Cerebrovascular Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2201)
# Related Disease Score Top Affiliating Genes
1 basal ganglia cerebrovascular disease 34.7 PLAT APOE
2 cerebral amyloid angiopathy, app-related 34.0 SERPINA3 APP APOE
3 stroke, ischemic 33.7 SERPINA3 SELP PLAT NOTCH3 MTHFR CX3CR1
4 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 33.6 SERPINA3 NOTCH3 HTRA1 COL4A1 APP APOE
5 vascular dementia 33.3 SERPINA3 NOTCH3 MTHFR CRP APP APOE
6 peripheral artery disease 33.3 SELP CRP APOE APOB APOA1 ACE
7 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 2 32.9 NOTCH3 HTRA1 CRP
8 disease of mental health 32.9 SERPINA3 MIR21 CRP APP APOE ACHE
9 col4a1-related familial vascular leukoencephalopathy 32.6 NOTCH3 HTRA1 COL4A1
10 cerebral atherosclerosis 32.5 SERPINA3 MTHFR CRP APOE APOA1 ACE
11 intracranial embolism 32.5 SELP PLAT CRP ACE
12 cerebral amyloid angiopathy, cst3-related 32.2 SERPINA3 APP APOE
13 carotid stenosis 32.2 SELP MTHFR CRP APOE ACE
14 transient cerebral ischemia 32.1 NOTCH3 MTHFR ACHE
15 vascular disease 32.0 SELP PLAT MTR MTHFR MIR21 CRP
16 dementia 31.9 SERPINA3 NOTCH3 HTRA1 APP APOE ACHE
17 anxiety 31.9 CRP APP APOE ACHE ACE
18 migraine with or without aura 1 31.8 NOTCH3 MTHFR HTRA1 CRP COL4A1 APOE
19 hypercholesterolemia, familial, 1 31.7 CRP APOE APOB APOA1 ACE
20 homocysteinemia 31.7 MTR MTHFR CRP APOE
21 sleep apnea 31.7 SELP CRP APOE APOB ACE
22 coronary heart disease 1 31.7 SELP PLAT MTHFR CX3CR1 CRP APOE
23 intracranial thrombosis 31.6 SELP PLAT MTHFR
24 peripheral vascular disease 31.6 SELP PLAT MTHFR CRP APOB APOA1
25 hyperlipoproteinemia, type iii 31.6 APOE APOB APOA1
26 lipid metabolism disorder 31.6 MIR21 CRP APOE APOB APOA1 ACE
27 arteriosclerosis 31.6 SELP MIR21 CRP APOE APOB APOA1
28 atherosclerosis susceptibility 31.5 SELP PLAT MTHFR CX3CR1 CRP APOE
29 carotid artery disease 31.5 SELP PLAT CRP APOE APOB APOA1
30 aphasia 31.5 PLAT APP APOE
31 arteries, anomalies of 31.5 SERPINA3 MIR21 CRP APOE APOB APOA1
32 angina pectoris 31.5 PLAT CRP APOA1 ACE
33 endocarditis 31.5 PLAT HTRA1 CRP
34 patent foramen ovale 31.4 PLAT NOTCH3 MTHFR CRP ACE
35 lipoprotein quantitative trait locus 31.4 SELP PLAT MIR21 CRP APOB APOA1
36 hydrocephalus 31.4 SERPINA3 PLAT MTHFR APP APOE ACE
37 intracranial berry aneurysm 31.4 SERPINA3 PLAT CRP APOE
38 atrial heart septal defect 31.4 PLAT MTHFR CRP ACE
39 thrombosis 31.4 SERPINA3 SELP PLAT MTHFR
40 mitral valve disease 31.4 SERPINA3 CRP AGTR1 ACE
41 ischemia 31.4 SELP PLAT MIR21 CX3CR1 APP ACE
42 arteriolosclerosis 31.3 SERPINA3 NOTCH3 HTRA1 APP APOE
43 retinal artery occlusion 31.3 MTHFR CRP ACE
44 binswanger's disease 31.3 NOTCH3 APP APOE ACHE
45 normal pressure hydrocephalus 31.3 SERPINA3 APP APOE ACE
46 aortic aneurysm 31.3 MIR21 CRP APOE ACE
47 retinal vascular disease 31.3 MTHFR MIR21 CRP ACE
48 intracranial aneurysm 31.3 PLAT APOE ACE
49 migraine with aura 31.3 NOTCH3 MTR MTHFR ACE
50 sleep disorder 31.3 CRP APOE ACE

Comorbidity relations with Cerebrovascular Disease via Phenotypic Disease Network (PDN): (show all 37)


Active Peptic Ulcer Disease Acute Cystitis
Alzheimer Disease Anxiety
Aortic Valve Disease 1 Basilar Artery Insufficiency
Benign Essential Hypertension Bronchitis
Cerebral Atherosclerosis Cerebral Degeneration
Decubitus Ulcer Deficiency Anemia
Encephalopathy Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Esophagitis Familial Atrial Fibrillation
Generalized Atherosclerosis Heart Disease
Hypertension, Essential Hypertensive Encephalopathy
Hypothyroidism Intermediate Coronary Syndrome
Intracranial Embolism Intracranial Thrombosis
Iron Deficiency Anemia Labyrinthitis
Malignant Essential Hypertension Mitral Valve Disease
Osteoporosis Parkinson Disease, Late-Onset
Peripheral Vascular Disease Protein-Energy Malnutrition
Schizophreniform Disorder Sinoatrial Node Disease
Swallowing Disorders Transient Cerebral Ischemia
Vertebral Artery Insufficiency

Graphical network of the top 20 diseases related to Cerebrovascular Disease:



Diseases related to Cerebrovascular Disease

Symptoms & Phenotypes for Cerebrovascular Disease

UMLS symptoms related to Cerebrovascular Disease:


seizures, edema, tremor, chest pain, back pain, angina pectoris, headache, syncope, pain, chronic pain, sciatica, vertigo/dizziness, equilibration disorder, sleeplessness, transient ischemic attacks, stereotypic symptoms

MGI Mouse Phenotypes related to Cerebrovascular Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.34 ACE ACHE AGTR1 APOA1 APOB APOE
2 cardiovascular system MP:0005385 10.29 ACE AGTR1 APOA1 APOB APOE APP
3 growth/size/body region MP:0005378 10.27 ACE ACHE AGTR1 APOB APOE APP
4 immune system MP:0005387 10.14 ACE AGTR1 APOB APOE APP COL4A1
5 mortality/aging MP:0010768 10.13 ACE ACHE AGTR1 APOB APOE APP
6 integument MP:0010771 10.02 APOA1 APOE APP CX3CR1 MTHFR NOTCH3
7 nervous system MP:0003631 9.9 ACHE AGTR1 APOB APOE APP COL4A1
8 muscle MP:0005369 9.86 ACHE APOB APOE APP COL4A1 CX3CR1
9 reproductive system MP:0005389 9.65 ACE ACHE APOB APOE APP COL4A1
10 vision/eye MP:0005391 9.32 ACHE APOB APOE COL4A1 CX3CR1 HTRA1

Drugs & Therapeutics for Cerebrovascular Disease

Drugs for Cerebrovascular Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1109)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Glyburide Approved Phase 4 10238-21-8 3488
2
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
3
Fosinopril Approved Phase 4 98048-97-6 55891
4
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
5
Azilsartan medoxomil Approved, Investigational Phase 4 863031-21-4
6
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
7
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
8
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
9
Nadroparin Approved, Investigational Phase 4
10
Eprosartan Approved Phase 4 133040-01-4 5281037
11
Zofenopril Approved Phase 4 81872-10-8
12
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
13
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
14
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
15
Galantamine Approved Phase 4 357-70-0 9651
16
Histamine Approved, Investigational Phase 4 51-45-6 774
17
Pantoprazole Approved Phase 4 102625-70-7 4679
18
Reteplase Approved, Investigational Phase 4 133652-38-7 65820
19
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
20
Phenindione Approved, Investigational Phase 4 83-12-5 4760
21
Ezetimibe Approved Phase 4 163222-33-1 150311
22
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
23
Doxazosin Approved Phase 4 74191-85-8 3157
24
Lercanidipine Approved, Investigational Phase 4 100427-26-7 65866
25
Manidipine Approved, Investigational Phase 4 89226-50-6
26
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
27
Paclitaxel Approved, Vet_approved Phase 4 33069-62-4 36314
28
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
29
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
30
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
31
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
32
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
33
Lenograstim Approved, Investigational Phase 4 135968-09-1
34
Tirofiban Approved Phase 4 144494-65-5 60947
35
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
36
Sotalol Approved Phase 4 3930-20-9, 959-24-0 5253
37
Propafenone Approved Phase 4 54063-53-5 4932
38
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
39
Haloperidol Approved Phase 4 52-86-8 3559
40
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
41
Ziprasidone Approved Phase 4 146939-27-7 60854
42
Trazodone Approved, Investigational Phase 4 19794-93-5 5533
43
Quinidine Approved, Investigational Phase 4 56-54-2 441074
44
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
45
Triflusal Approved, Investigational Phase 4 322-79-2
46
Insulin aspart Approved Phase 4 116094-23-6 16132418
47
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
48
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
49
Reboxetine Approved, Experimental Phase 4 98769-81-4, 71620-89-8 123628 65856
50
Tizanidine Approved, Investigational Phase 4 51322-75-9 5487

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Study of Influence of Timing on Motor Learning Unknown status NCT02048826 Phase 4
2 Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage Alzheimer's Disease Having Coexisting Small Vessel Cerebrovascular Disease Unknown status NCT02444637 Phase 4 Rivastigmine
3 Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) Unknown status NCT00108706 Phase 4 Candesartan
4 Dose-response Relationship of Botullinum Toxin (DWP 450) for Finger Flexor Spasticity Unknown status NCT03517319 Phase 4 Normal Saline 0.9% 1.2 ml;Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 15 U;Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 30 U;Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 50 U;Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 70 U
5 The Early Diagnosis and Prevention of Ischemic Stroke and Cognition Decline Associated With Coronary Artery Disease Combined With Cerebral Artery Stenosis or Arrhythmia by 24-Hour Simultaneous Recorder of Electrocardiograph and Electroencephalography Unknown status NCT00247533 Phase 4
6 Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography Unknown status NCT02826200 Phase 4 Acenocoumarol
7 Efficacy of "Equistasi" on the Gait of Patients Affected by Hemiparesis Due to Cerebrovascular Accident Unknown status NCT02714478 Phase 4
8 Effects of the Use of "de Novo" Everolimus for the Expression of Cytokines in Kidneys From Extended Criteria Donors and With Delayed Graft Function Unknown status NCT01663805 Phase 4 Everolimus
9 Remifentanil for c-Section With General Anesthesia in Severe Preeclamptic Patients Unknown status NCT00567957 Phase 4 Remifentanil;Saline
10 Comparison of the Efficacy of Everolimus-Eluting Versus Sirolimus-Eluting Stent for Coronary Lesions Unknown status NCT00698607 Phase 4 6-month clopidogrel therapy;12-month clopidogrel therapy
11 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Unknown status NCT02478346 Phase 4 Fluorescein Sodium
12 Preventive Effects of Ginseng Against Atherosclerosis and Subsequent Ischemic Stroke: A Randomized Controlled Trial Unknown status NCT02796664 Phase 4
13 A Randomized Controlled Study of Nifecardia SRFC (Nifedipine) and Adalat OROS (Nifedipine) in the Treatment of Patients With Essential Hypertension Unknown status NCT00173667 Phase 4 Nifedipine 30 mg GITS
14 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Astragalus Membranaceus in the Patients After Stroke With Fatigue Unknown status NCT01554787 Phase 4 Chinese Herb Astragalus membranaceus
15 Phase IV Clinical Trial of Yiqitongluo Granule in the Treatment of Stroke With Qi-deficiency and Blood-stasis Syndrome Unknown status NCT02604654 Phase 4 Yiqitongluo granule
16 Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis - High-Resolution Magnetic Resonance Imaging Study (STAMINA-MRI Study) Unknown status NCT02458755 Phase 4 High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg
17 The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial Unknown status NCT00724724 Phase 4 Butylphthalide Soft Capsules;Aspirin
18 Effect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment: An Open and Randomized Clinical Trial Unknown status NCT00813722 Phase 4 amlodipine (calcium chanel blocker) and losartan (at1 antagonist);atenolol (beta blocker) and hydrochlorothiazide (diuretic)
19 A Double Blind, Placebo Controlled Study to Evaluate the Efficacy of Melatonin in Acute Ischemic Stroke. Unknown status NCT01863277 Phase 4 Melatonin;placebo
20 Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol Unknown status NCT02403349 Phase 4 Fimasartan;Valsartan;Atenolol
21 Effects on Clinical and Functional Outcome of Escitalopram in Adult Stroke Unknown status NCT00967408 Phase 4 Escitalopram;Placebo
22 The Effectiveness of Ultrasound Guided Sub-acromial Bursa Injection With Botulinum Toxin A in for Refractory Shoulder Pain After Stroke. Unknown status NCT02618603 Phase 4 Botulinum toxin A;Triamcinolone Acetonide
23 Improving Stroke Prevention in Atrial Fibrillation Through Pharmacist Prescribing: Program for the Identification of 'Actionable' AF (PIAAF) Rx Study Unknown status NCT03126214 Phase 4 Anticoagulants
24 Functional Electrical Stimulation (FES)-Assisted Walking: Enhancement of Voluntary Walking Function Among Persons With Severe Hemiplegia Post-Stroke Unknown status NCT00552916 Phase 4
25 Device Closure Versus Medical Therapy for Secondary Prevention in Cryptogenic Stroke Patients With High-Risk Patent Foramen Ovale : DEFENSE-PFO Unknown status NCT01550588 Phase 4 Standard medical treatment
26 Nimodipine Preventing Cognitive Impairment in Ischemic Cerebrovascular Events: A Randomized, Placebo-Controlled, Double-Blind Trial (NICE) Unknown status NCT01220622 Phase 4 Nimodipine;Placebo
27 CHADSS: Chagas Disease Scan Study Unknown status NCT01650792 Phase 4 Aspirin
28 A Random, Double-blind, Parallel, Placebo-controlled, Multi-center Study of Shuxuetong for Prevention of Recurrence in Acute Cerebrovascular Events With Embolism Unknown status NCT03090113 Phase 4 Shuxuetong Injection;Placebo Injection
29 Study on the Efficacy of Alprostadil Injection in Patients With Acute Ischemic Stroke Unknown status NCT03252626 Phase 4 Alprostadil;Normal saline
30 The THERAPY Trial: The Randomized, Concurrent Controlled Trial to Assess the Penumbra System's Safety and Effectiveness in the Treatment of Acute Stroke Unknown status NCT01429350 Phase 4 intravenous (IV) recombinant human tissue plasminogen activator (rtPA)
31 A Randomized Controlled Trial of Rectus Femoris Tenotomy Versus Botulinum Toxin A for Stiff Knee Gait After Stroke Unknown status NCT02114736 Phase 4 Botulinum Toxin injection in the rectus femoris muscle
32 Phase III Study of Botulinum Toxin A Injection for Lower Limbs Spasticity in Subacute Stroke Adults Unknown status NCT02505802 Phase 4 BoNT-A injection
33 A Phase IV, Double Blind, Placebo-controlled, Randomized, Multi-Center Study to Evaluate the Efficacy of Huatuo Zaizao Pills in Improving of Neural Function in Acute Ischemic Stroke Unknown status NCT01758536 Phase 4 Huatuo Zaizao Pills
34 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
35 The Hypertension in the Very Elderly Trial (HYVET) Unknown status NCT00122811 Phase 4 Indapamide SR 1.5mg; Perindopril 2-4mg
36 Validation of Stroke Volume Variation and Pleth Variability Index as Predictors of Fluid Responsiveness in Patients Undergoing Robot Assisted Thyroidectomy Unknown status NCT02122367 Phase 4
37 Prospective, Randomized, Open-label, Blinded Endpoints, Multi-center Study to Evaluate the Efficacy of Modest Blood Pressure Reduction With Diovan® (Valsartan) in Acute Ischemic Stroke Unknown status NCT00874601 Phase 4 Diovan® (valsartan)
38 The Efficacy and Safety of Dabigatran Etexilate and Different Intensity Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation Unknown status NCT02646267 Phase 4 standard intensity warfarin;low intensity warfarin;dabigatran etexilate
39 Upper Extremity Rehabilitation Using Robot and Botulinum Toxin Unknown status NCT02228863 Phase 4
40 Efficacy of Creative Therapy for Stroke Patients Unknown status NCT01455155 Phase 4
41 Phase IV Study for Effect of Intensive Blood-Pressure Control Using Anti-hypertensive Agents in Essential Hypertension With History of Stroke Unknown status NCT01198496 Phase 4 Losartan, Losartan and HCTZ, Amlodipine , Spironolactone
42 The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack.10 vs 30 Days of Combination ASA and Clopidogrel Study Unknown status NCT02144831 Phase 4 anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)
43 Double Blind Placebo Controlled Multicenter Trial for Prevention of IMT Progression in the Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage With Cilostazol and Probucol Unknown status NCT02483169 Phase 4 cilostazol;Probucol;Aspirin;placebo of cilostazol;Placebo of aspirin
44 Exploratory Study on the Effects of Early Rosuvastatin Treatment in Patients With Acute Ischemic Stroke Unknown status NCT02643784 Phase 4 Rosuvastatin
45 Early Warning and Optimization Strategy in Carotid Endarterectomy Unknown status NCT01210937 Phase 4
46 Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke Unknown status NCT00747279 Phase 4 Intensive insulin therapy
47 A Randomized Double Blind Placebo Control Study of Huang-Chi-Wu-Wu- Tang in Patients With Intracranial Arterial Stenosis Unknown status NCT01553643 Phase 4 Chinese Herb Huang-Chi-Wu-Wu-Tang;placebo
48 Effects of Vernakalant and Flecainide on Atrial Contractility in Patients With Atrial Fibrillation Unknown status NCT01646281 Phase 4 Vernakalant;Flecainide
49 Randomized Controlled Trial to Evaluate Implanted Event Recorders for the First Diagnosis of Atrial Fibrillation in High-risk Patients Unknown status NCT01461434 Phase 4
50 Randomized, Double-blind, Placebo-controlled Study of the Effect of Cerebrolysin® (EVER Neuro Pharma GmbH, Austria) at the Level of Paresis of the Upper Limb When Used in Complex Therapy of Acute Ischemic Stroke Unknown status NCT02581371 Phase 4 Cerebrolysin infusion

Search NIH Clinical Center for Cerebrovascular Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Pentoxifylline
Warfarin
Warfarin Sodium
WARFARIN SODIUM ISOPROPANOL COMPLEX

Cochrane evidence based reviews: cerebrovascular disorders

Genetic Tests for Cerebrovascular Disease

Anatomical Context for Cerebrovascular Disease

MalaCards organs/tissues related to Cerebrovascular Disease:

40
Brain, Heart, Testes, Endothelial, Kidney, Bone, Lung

Publications for Cerebrovascular Disease

Articles related to Cerebrovascular Disease:

(show top 50) (show all 16971)
# Title Authors PMID Year
1
Acetazolamide improves cerebral hemodynamics in CADASIL. 61 54
20227091 2010
2
The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. 61 54
20485689 2010
3
The angiotensin II type 2 receptor in the brain. 54 61
19861353 2010
4
Lipids and carotid plaque in the Northern Manhattan Study (NOMAS). 61 54
20028534 2009
5
APOE-related mortality: effect of dementia, cardiovascular disease and gender. 54 61
18237822 2009
6
Apolipoprotein B levels, APOB alleles, and risk of ischemic cardiovascular disease in the general population, a review. 54 61
19200547 2009
7
Observation of the density and size of cells in hippocampus and vascular lesion in thalamus of GFAP-apoE transgenic mice. 61 54
19633698 2009
8
Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease. 61 54
18985627 2009
9
The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy. 54 61
19417859 2009
10
CADASIL: extended polymorphisms and mutational analysis of the NOTCH3 gene. 61 54
19006080 2009
11
Report of two Chinese families and a review of Mainland Chinese CADASIL patients. 61 54
19167727 2009
12
MRI correlates of cognitive decline in CADASIL: a 7-year follow-up study. 54 61
19139365 2009
13
Education attenuates the effect of medial temporal lobe atrophy on cognitive function in Alzheimer's disease: the MIRAGE study. 54 61
19542606 2009
14
Age and apoE associations with complex pathologic features in Alzheimer's disease. 54 61
18653200 2008
15
Association of apolipoprotein E genotype and cerebrovascular disease risk factors in a Turkish population. 61 54
18576210 2008
16
Cystatin C expression in ischemic white matter lesions. 61 54
18261165 2008
17
The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. 61 54
18548143 2008
18
Association of blood pressure and genetic background with white matter lesions in patients with mild cognitive impairment. 61 54
18511756 2008
19
New biochemical markers in acute coronary syndromes. 61 54
18537608 2008
20
PPAR-gamma Pro12Ala genotype and risk of cognitive decline in elders. 54 61
17052804 2008
21
Specific P-selectin and P-selectin glycoprotein ligand-1 genotypes/haplotypes are associated with risk of incident CHD and ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. 54 61
17420019 2007
22
Polymorphisms of the renin-angiotensin system are associated with blood pressure, atherosclerosis and cerebral white matter pathology. 61 54
17220293 2007
23
Polymorphisms in apolipoprotein B and risk of ischemic stroke. 54 61
17595251 2007
24
The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. 54 61
17534460 2007
25
Silent brain infarction and platelet activation in obstructive sleep apnea. 61 54
17341649 2007
26
Increased plasma levels of asymmetric dimethylarginine in patients with carotid stenosis: no evidence for the role of the common FABP2 A54T gene polymorphism. 54 61
17212611 2007
27
Delapril plus indapamide: a review of the combination in the treatment of hypertension. 54 61
17506588 2007
28
A perspective on telmisartan and cardiovascular risk. 61 54
17938615 2007
29
Cognitive impact of subcortical vascular and Alzheimer's disease pathology. 61 54
17192928 2006
30
Amyloid beta-peptide preconditioning reduces glutamate-induced neurotoxicity by promoting endocytosis of NMDA receptor. 54 61
17054909 2006
31
Cerebrovascular disease, APOE epsilon4 allele and cognitive decline in a cognitively normal population. 54 61
16945218 2006
32
Association of homocysteine (but not of MTHFR 677 C>T, MTR 2756 A>G, MTRR 66 A>G and TCN2 776 C>G) with ischaemic cerebrovascular disease in Sicily. 61 54
16894458 2006
33
Cognitive frailty: Predementia syndrome and vascular risk factors. 61 54
16023766 2006
34
Transient global amnesia in a patient with high and persistent levels of antiphospholipid antibodies. 54 61
16208431 2006
35
[The relationship between ApoE gene polymorphism and lipid parameters]. 54 61
16335008 2005
36
The spectrum of mutations for CADASIL diagnosis. 61 54
15995828 2005
37
Genetic variation of the intestinal fatty acid-binding protein 2 gene in carotid atherosclerosis. 61 54
16013194 2005
38
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephaloapthy (CADASIL): a hereditary cerebrovascular disease, which can be diagnosed by skin biopsy electron microscopy. 61 54
15798438 2005
39
Adverse associations between CX3CR1 polymorphisms and risk of cardiovascular or cerebrovascular disease. 54 61
15681302 2005
40
Leukocytosis and ischemic vascular disease morbidity and mortality: is it time to intervene? 61 54
15662026 2005
41
T280M and V249I polymorphisms of fractalkine receptor CX3CR1 and ischemic cerebrovascular disease. 54 61
15644279 2005
42
[Mutations of genes associated with thromboses in ischemic stroke in patients with primary antiphospholipid syndrome]. 54 61
16320685 2005
43
Carotid artery intima-media thickness and angiotensin-converting enzyme gene polymorphism in the offspring of parents with premature stroke. 54 61
15858957 2005
44
The FABP2 gene polymorphism in cerebrovascular disease. 54 61
15527447 2004
45
RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. 61 54
15459432 2004
46
ACE genotype and cognitive decline in an African-Caribbean population. 61 54
15465635 2004
47
Plasma adrenomedullin and carotid atherosclerosis in atherothrombotic ischemic stroke. 54 61
15361766 2004
48
123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. 54 61
15471834 2004
49
Vascular injury in systemic sclerosis: angiotensin-converting enzyme insertion/deletion polymorphism. 54 61
15016346 2004
50
Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. 61 54
15161326 2004

Variations for Cerebrovascular Disease

Expression for Cerebrovascular Disease

Search GEO for disease gene expression data for Cerebrovascular Disease.

Pathways for Cerebrovascular Disease

Pathways related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.37 MTR MTHFR APOE APOB APOA1
2
Show member pathways
11.57 COL4A1 APOE APOB APOA1
3
Show member pathways
11.56 SERPINA3 PLAT MTR MTHFR CRP APOE
4 11.18 SELP PLAT APOB
5 10.76 CX3CR1 APP APOE ACE
6 10.69 PLAT APP ACE
7 10.48 MEG3 HOTAIR

GO Terms for Cerebrovascular Disease

Cellular components related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 10.18 SERPINA3 PLAT MIR21 HTRA1 APP APOE
2 cell surface GO:0009986 9.99 PLAT NOTCH3 CX3CR1 APP APOA1 ACHE
3 extracellular region GO:0005576 9.93 SERPINA3 PLAT NOTCH3 HTRA1 CRP COL4A1
4 endoplasmic reticulum lumen GO:0005788 9.89 COL4A1 APP APOE APOB APOA1
5 collagen-containing extracellular matrix GO:0062023 9.88 SERPINA3 PLAT HTRA1 COL4A1 APOE APOA1
6 high-density lipoprotein particle GO:0034364 9.63 APOE APOB APOA1
7 very-low-density lipoprotein particle GO:0034361 9.61 APOE APOB APOA1
8 endocytic vesicle lumen GO:0071682 9.54 APOE APOB APOA1
9 low-density lipoprotein particle GO:0034362 9.5 APOE APOB APOA1
10 discoidal high-density lipoprotein particle GO:0034365 9.48 APOE APOA1
11 extracellular space GO:0005615 9.44 SERPINA3 SELP PLAT MIR21 HTRA1 CRP
12 chylomicron GO:0042627 9.43 APOE APOB APOA1
13 intermediate-density lipoprotein particle GO:0034363 9.13 APOE APOB APOA1

Biological processes related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.91 APP APOE APOB APOA1
2 platelet degranulation GO:0002576 9.8 SERPINA3 SELP APP APOA1
3 cholesterol metabolic process GO:0008203 9.78 APP APOE APOB APOA1
4 retinoid metabolic process GO:0001523 9.76 APOE APOB APOA1
5 intermembrane lipid transfer GO:0120009 9.71 APOE APOB APOA1
6 high-density lipoprotein particle assembly GO:0034380 9.63 APOE APOA1
7 phospholipid efflux GO:0033700 9.63 APOE APOA1
8 artery morphogenesis GO:0048844 9.63 NOTCH3 APOE APOB
9 amyloid precursor protein metabolic process GO:0042982 9.62 APOE ACHE
10 high-density lipoprotein particle clearance GO:0034384 9.62 APOE APOA1
11 methionine biosynthetic process GO:0009086 9.61 MTR MTHFR
12 lipoprotein metabolic process GO:0042157 9.61 APOE APOB APOA1
13 chylomicron remnant clearance GO:0034382 9.6 APOE APOB
14 very-low-density lipoprotein particle remodeling GO:0034372 9.59 APOE APOA1
15 regulation of Cdc42 protein signal transduction GO:0032489 9.58 APOE APOA1
16 cholesterol efflux GO:0033344 9.58 APOE APOB APOA1
17 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.57 AGTR1 ACE
18 very-low-density lipoprotein particle clearance GO:0034447 9.56 APOE APOB
19 lipoprotein catabolic process GO:0042159 9.55 APOE APOB
20 low-density lipoprotein particle remodeling GO:0034374 9.54 APOE APOB AGTR1
21 positive regulation of amyloid fibril formation GO:1905908 9.52 APP APOE
22 positive regulation of phospholipid efflux GO:1902995 9.51 APOE APOA1
23 negative regulation of long-term synaptic potentiation GO:1900272 9.5 CX3CR1 APP APOE
24 chylomicron assembly GO:0034378 9.43 APOE APOB APOA1
25 chylomicron remodeling GO:0034371 9.33 APOE APOB APOA1
26 positive regulation of cholesterol esterification GO:0010873 9.13 APOE APOA1 AGTR1
27 lipoprotein biosynthetic process GO:0042158 8.8 APOE APOB APOA1

Molecular functions related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 10 NOTCH3 HTRA1 CRP APP APOE APOA1
2 heparin binding GO:0008201 9.62 SELP APP APOE APOB
3 amyloid-beta binding GO:0001540 9.61 APOE APOA1 ACHE
4 lipid transporter activity GO:0005319 9.43 APOE APOB APOA1
5 lipoprotein particle binding GO:0071813 9.4 APOE APOA1
6 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.37 APOE APOA1
7 bradykinin receptor binding GO:0031711 9.16 AGTR1 ACE
8 low-density lipoprotein particle receptor binding GO:0050750 9.13 CRP APOE APOB
9 intermembrane cholesterol transfer activity GO:0120020 8.8 APOE APOB APOA1

Sources for Cerebrovascular Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....